[
    {
        "pregunta": "1. What is the recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline?",
        "respuesta": "The recommended treatment approach for DMARD-naive patients with moderate-to-high disease activity in rheumatoid arthritis, according to the 2021 American College of Rheumatology guideline, is the use of methotrexate monotherapy over hydroxychloroquine or sulfasalazine. This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine.",
        "contexto": [
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|\n|---|---|---|---|\n|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |\n|Methotrexate monotherapy is strongly recommended over:| | | |\n|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|\n|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|",
            "|Initiation of treatment in DMARD-naive patients with low disease activity| | | |\n|Hydroxychloroquine is conditionally recommended over other csDMARDs.|Very low|PICO 1a.C1–4|p. 1–6|\n|Sulfasalazine is conditionally recommended over methotrexate.|Very low|PICO 1a.C2|p. 2|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|\n|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#| | | |",
            "| Rheumatoid arthritis should be treated with disease-modifying antirheumatic drugs and follow a treat-to-target management strategy, as detailed in the 2021 ACR Rheumatoid Arthritis Pharmacologic Treatment Guidelines (1). |\n| Individuals with chronic diseases like rheumatoid arthritis seek many available therapies to maintain physical function, reduce pain, and improve their quality of life. |",
            "both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on"
        ]
    },
    {
        "pregunta": "2. In patients with subcutaneous nodules and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "Based on the 2021 American College of Rheumatology guideline, the preferred DMARD therapy for patients with subcutaneous nodules and moderate-to-high disease activity is methotrexate.",
        "contexto": [
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)|Supp. App. 2|\n|---|---|---|---|\n|Subcutaneous nodules| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.|Very low|PICO 64|p. 427|",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "preferences. The voting panel cautioned that many patients treated with certain monoclonal antibodies may require ongoing treatment with methotrexate to prevent the formation of antidrug antibodies Recommendations for specific patient populations (Table 6) Subcutaneous nodules Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-tohigh disease activity Switching to a non-methotrexate DMARD is conditionally recommended over",
            "|Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules.|Very low|PICO 65|p. 428|\n|Pulmonary disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity.|Very low|PICO 67|p. 430|",
            "|Initiation of treatment in DMARD-naive patients with low disease activity| | | |\n|Hydroxychloroquine is conditionally recommended over other csDMARDs.|Very low|PICO 1a.C1–4|p. 1–6|\n|Sulfasalazine is conditionally recommended over methotrexate.|Very low|PICO 1a.C2|p. 2|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|\n|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#| | | |"
        ]
    },
    {
        "pregunta": "3. For patients with pulmonary disease and moderate-to-high disease activity, what is the recommended DMARD treatment according to the guideline?",
        "respuesta": "I'm sorry, based on the information provided, there is no specific recommendation in the documents for DMARD treatment for patients with pulmonary disease and moderate-to-high disease activity in rheumatoid arthritis according to the 2021 American College of Rheumatology guideline.",
        "contexto": [
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "for patients who are candidates for, or are currently receiving checkpoint inhibitor therapy. We anticipate that additional recommendations for patients with systemic rheumatic diseases and solid malignancies will be developed as further data become available. There were vigorous discussions pertaining to recommendations for specific DMARDs in patients with moderate-tohigh disease activity despite csDMARDs and with a history of serious infection. However, the evidence was insufficient to",
            "both pharmacologic and nonpharmacologic treatment). After excluding 18,333 titles Recommendations for DMARD-naive patients with moderate-to-high disease activity (Table 2 DMARD monotherapy Methotrexate is strongly recommended over hydroxychloroquine or sulfasalazine for DMARDnaive patients with moderate-to-high disease activity This recommendation is strongly in favor of methotrexate despite very low-certainty evidence for hydroxychloroquine and low-certainty evidence for sulfasalazine based on",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|\n|---|---|---|---|\n|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |\n|Methotrexate monotherapy is strongly recommended over:| | | |\n|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|\n|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|"
        ]
    },
    {
        "pregunta": "4. What is the suggested course of action for patients with heart failure and inadequate response to csDMARDs, as per the guideline?",
        "respuesta": "The suggested course of action for patients with heart failure and inadequate response to csDMARDs, according to the 2021 American College of Rheumatology guideline, is to consider the addition of a non-TNF inhibitor bDMARD or tsDMARD over the addition of a TNF inhibitor or to switch to a non-TNF inhibitor bDMARD or tsDMARD over continuing with a TNF inhibitor. These recommendations are conditionally made based on the risk of worsening heart failure observed in clinical trials.",
        "contexto": [
            "or IV heart failure and an inadequate response to csDMARDs Switching to a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure These recommendations are based on the risk of worsening heart failure observed in randomized clinical trials of TNF inhibitors in patients with NYHA class III or IV heart failure without RA Lymphoproliferative disorder Rituximab is conditionally recommended",
            "for patients who are candidates for, or are currently receiving checkpoint inhibitor therapy. We anticipate that additional recommendations for patients with systemic rheumatic diseases and solid malignancies will be developed as further data become available. There were vigorous discussions pertaining to recommendations for specific DMARDs in patients with moderate-tohigh disease activity despite csDMARDs and with a history of serious infection. However, the evidence was insufficient to",
            "|Heart failure| | | |\n|Addition of a non–TNF inhibitor bDMARD or tsDMARD is conditionally recommended over addition of a TNF inhibitor for patients with NYHA class III or IV heart failure and an inadequate response to csDMARDs.|Very low|PICO 70|p. 435|\n|Switching to a non–TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure.|Very low|PICO 71|p. 436|\n|Lymphoproliferative disorder| | | |",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "| Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options under consideration. |\n| Recommendations are limited to DMARDs approved by the US FDA for treatment of RA.                                                                |\n| csDMARDs: hydroxychloroquine, sulfasalazine, methotrexate, leflunomide.                                                                         |"
        ]
    },
    {
        "pregunta": "5. In patients with lymphoproliferative disorder and moderate-to-high disease activity, what is the preferred DMARD therapy based on the guideline?",
        "respuesta": "The preferred DMARD therapy for patients with lymphoproliferative disorder and moderate-to-high disease activity, according to the 2021 American College of Rheumatology guideline, is rituximab.",
        "contexto": [
            "RA Lymphoproliferative disorder Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity Rituximab is preferred over other DMARDs, regardless of previous DMARD experience, because it would not be expected to increase the risk of recurrence or worsening of these lymphoproliferative disorders. The recommendation is conditional because of the",
            "to clinicians. This preference was also stated in the 2015 guidelines When clinically relevant, recommendations specify the level of disease activity in the patient population (Table 1 7 In summary, this update includes recommendations related to initiation and adjustment of DMARD therapy in patients with RA. It also emphasizes the importance of minimizing use of glucocorticoids. It is expected that additional data may modify the direction and/or strength of specific recommendations. The ACR",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "|Initiation of treatment in DMARD-naive patients with low disease activity| | | |\n|Hydroxychloroquine is conditionally recommended over other csDMARDs.|Very low|PICO 1a.C1–4|p. 1–6|\n|Sulfasalazine is conditionally recommended over methotrexate.|Very low|PICO 1a.C2|p. 2|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|\n|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#| | | |",
            "|Lymphoproliferative disorder| | | |\n|Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity.|Very low|PICO 75 and PICO 76|p. 446–7|\n|Hepatitis B infection| | | |"
        ]
    },
    {
        "pregunta": "6. How should healthcare providers manage patients with hepatitis B infection initiating rituximab therapy, as per the guideline?",
        "respuesta": "Healthcare providers should strongly recommend prophylactic antiviral therapy over frequent monitoring alone for patients initiating rituximab who are hepatitis B core antibody positive, regardless of hepatitis B surface antigen status. Additionally, it is strongly recommended to provide prophylactic antiviral therapy over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive. Frequent monitoring alone of viral load and liver enzymes is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative.",
        "contexto": [
            "|Hepatitis B infection| | | |\n|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status).|Very low|PICO 82|p. 459|",
            "disorders. The recommendation is conditional because of the very low-certainty evidence supporting this PICO question. Hepatitis B infection Prophylactic antiviral therapy is strongly recommended over frequent monitoring of viral load and liver enzymes alone for patients initiating rituximab who are hepatitis B core antibody positive (regardless of hepatitis B surface antigen status) Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating",
            "|Prophylactic antiviral therapy is strongly recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive.|Very low|PICO 83|p. 464|",
            "antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over",
            "recommended over frequent monitoring alone for patients initiating any bDMARD or tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen positive Frequent monitoring alone of viral load and liver enzymes is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative These recommendations were made based on the risk of"
        ]
    },
    {
        "pregunta": "7. What is the recommended approach for DMARD-naive patients with nonalcoholic fatty liver disease and moderate-to-high disease activity, according to the guideline?",
        "respuesta": "The recommended approach for DMARD-naive patients with nonalcoholic fatty liver disease and moderate-to-high disease activity, according to the guideline, is the conditional recommendation of using methotrexate over alternative DMARDs. This recommendation applies to patients with normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis.",
        "contexto": [
            "|Nonalcoholic fatty liver disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for DMARD-naive patients with nonalcoholic fatty liver disease, normal liver enzymes and liver function tests, and no evidence of advanced liver fibrosis who have moderate-to-high disease activity.|Very low|PICO 87|p. 489|\n|Persistent hypogammaglobulinemia without infection| | | |",
            "|Frequent monitoring alone is conditionally recommended over prophylactic antiviral therapy for patients initiating a bDMARD other than rituximab or a tsDMARD who are hepatitis B core antibody positive and hepatitis B surface antigen negative.|Very low|PICO 84|p. 471|\n|Nonalcoholic fatty liver disease| | | |",
            "there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients who are in remission. In this update, tapering recommendations are made for patients who are in low disease activity or",
            "Recommendation for patients who have been treated with csDMARDs, excluding methotrexate, and who have moderate-to-high disease activity (Table 2) Recommendations are the same as for DMARD-naive patients except for this population. The strength of the following recommendation is conditional for all bDMARDs and tsDMARDs. Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD The recommendation is conditional because the voting panel",
            "|Initiation of treatment in DMARD-naive patients with low disease activity| | | |\n|Hydroxychloroquine is conditionally recommended over other csDMARDs.|Very low|PICO 1a.C1–4|p. 1–6|\n|Sulfasalazine is conditionally recommended over methotrexate.|Very low|PICO 1a.C2|p. 2|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|\n|Initiation of treatment in csDMARD-treated, but methotrexate-naive, patients with moderate-to-high disease activity#| | | |"
        ]
    },
    {
        "pregunta": "8. In patients with persistent hypogammaglobulinemia without infection, what is the guideline's recommendation regarding rituximab therapy continuation?",
        "respuesta": "The guideline's recommendation regarding rituximab therapy continuation in patients with persistent hypogammaglobulinemia without infection is that continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD. This recommendation is based on the uncertain clinical significance of hypogammaglobulinemia in patients without infection and the need to balance infection risk with maintaining disease control.",
        "contexto": [
            "|Persistent hypogammaglobulinemia without infection| | | |\n|In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD.|Very low|PICO 66|p. 429|\n|Previous serious infection| | | |",
            "|Recommendation: For patients with GPA/MPA receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (e.g., IgG &lt;3 gm/liter) and recurrent severe infections, we conditionally recommend immunoglobulin supplementation.|44|Very low|\n|Ungraded position statement: The duration of non-GC remission maintenance therapy in GPA/MPA should be guided by the patient’s clinical condition, preferences, and values.|26|Low to moderate|",
            "antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over",
            "rituximab therapy for patients at target is conditionally recommended over switching to a different bDMARD or tsDMARD Continuing rituximab in patients who are at target is preferred because of the uncertain clinical significance of hypogammaglobulinemia in patients without infection. Although an increased risk of infection has been described in RA patients with hypogammaglobulinemia, it is not known if a switch in DMARDs in patients who are at target is more effective in lowering infection risk",
            "in patients who are at target is more effective in lowering infection risk while maintaining disease control than continuation of rituximab. The recommendation is conditional because physician and patient risk tolerance is likely to vary depending on the degree of hypogammaglobulinemia and patient-specific risk factors for infection. Previous serious infection Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the"
        ]
    },
    {
        "pregunta": "9. For patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity, what is the recommended treatment approach according to the guideline?",
        "respuesta": "Based on the information provided in the retrieved documents, the recommended treatment approach for patients with a history of serious infection within the previous 12 months and moderate-to-high disease activity, according to the guideline, is the conditional recommendation of adding a csDMARD over adding a bDMARD or tsDMARD for patients who have not responded adequately to csDMARD monotherapy. This recommendation is based on very low-certainty evidence and highlights the need for further research to support specific recommendations for this patient population.",
        "contexto": [
            "|Previous serious infection| | | |\n|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 88|p. 490|",
            "a history of serious infection. However, the evidence was insufficient to support a recommendation. Future studies (using large registries and network meta-analyses) are needed to support specific recommendations for this patient population. The recommendation statements in this update are not directly comparable to the ACR 2015 guidelines  because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend",
            "over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity This conditional recommendation is made based on observational studies suggesting a strong association between dose and duration of glucocorticoids with the risk of serious infection Nontuberculous mycobacterial (NTM) lung disease Given the variability of NTM lung disease severity and response to treatment, patients should be closely",
            "|Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity.|Very low|PICO 90 and PICO 91|p. 496–7|\n|Nontuberculous mycobacterial lung disease| | | |",
            "of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy This conditional recommendation is made based on observational data suggesting a lower risk of infection associated with combination csDMARDs (dual or triple therapy) compared to bDMARDs or tsDMARDs Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a"
        ]
    },
    {
        "pregunta": "10. How should healthcare providers manage patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy, based on the guideline's recommendations?",
        "respuesta": "Based on the retrieved documents, healthcare providers should consider adding csDMARDs over adding a bDMARD or tsDMARD for patients with nontuberculous mycobacterial lung disease and moderate-to-high disease activity despite csDMARD monotherapy. Additionally, abatacept is conditionally recommended over other bDMARDs and tsDMARDs for this patient population based on very low-certainty evidence. These recommendations are made to address the disease activity in patients with nontuberculous mycobacterial lung disease while considering the risks associated with different DMARD therapies.",
        "contexto": [
            "|Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARD monotherapy.|Very low|PICO 92|p. 498|\n|Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with nontuberculous mycobacterial lung disease who have moderate-to-high disease activity despite csDMARDs.|Very low|PICO 93|p. 499|</p>",
            "in patients receiving either inhaled or oral glucocorticoids Addition of csDMARDs is conditionally recommended over addition of a bDMARD or tsDMARD for patients with NTM lung disease who have moderate-to-high disease activity despite csDMARD monotherapy This recommendation is based on the lower expected risk of NTM lung disease associated with csDMARDs compared to bDMARDs and tsDMARDs Abatacept is conditionally recommended over other bDMARDs and tsDMARDs for patients with NTM lung disease who",
            "over other bDMARDs and tsDMARDs for patients with NTM lung disease who have moderate-tohigh disease activity despite csDMARDs Abatacept is conditionally recommended over other bD MARDs and tsDMARDs based on population data extrapolated from studies on tuberculosis The preceding 3 recommendations are conditional because of the very low-certainty evidence supporting the analysis of the differences in treatment outcomes posed by these PICO questions. DISCUSSION The ACR guidelines were developed to",
            "|Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity.|Very low|PICO 90 and PICO 91|p. 496–7|\n|Nontuberculous mycobacterial lung disease| | | |",
            "|Nontuberculous mycobacterial lung disease| | | |\n|Use of the lowest possible dose of glucocorticoids (discontinuation if possible) is conditionally recommended over continuation of glucocorticoids for patients with nontuberculous mycobacterial lung disease.|Very low|No relevant PICO| |"
        ]
    }
]